{
    "clinical_study": {
        "@rank": "99221", 
        "arm_group": [
            {
                "arm_group_label": "Intranasal oxytocin", 
                "arm_group_type": "Active Comparator", 
                "description": "Intranasal oxytocin. 16 IU intranasal oxytocin x 5 days.  One month interval between arms of treatment."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be administered via nasal spray - 1 spray in each nostril x5 days."
            }
        ], 
        "brief_summary": {
            "textblock": "Individuals with Prader-Willi syndrome (PWS) have been found to have a deficit of\n      oxytocin-producing neurons and decreased oxytocin receptor gene function, so the purpose of\n      this study is to determine if oxytocin (OT) administration will improve some of the aspects\n      of Prader-Willi syndrome that are particularly troublesome for children and their families\n      (the insatiable appetite and social behaviors).\n\n      The research questions are:\n\n        1. Does intranasal oxytocin cause any side effects in children with PWS?\n\n        2. Does intranasal oxytocin administration alter appetite or behaviors in PWS?"
        }, 
        "brief_title": "Oxytocin Trial in Prader-Willi Syndrome", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prader Willi Syndrome", 
        "condition_browse": {
            "mesh_term": "Prader-Willi Syndrome"
        }, 
        "detailed_description": {
            "textblock": "This study is to investigate if intranasal oxytocin will improve hyperphagia, social skills,\n      and behaviors in subjects with Prader-Willi syndrome. This will be a randomized placebo\n      controlled pilot study. The primary outcome measure is to determine if intranasal\n      administration of oxytocin will cause any adverse events in subjects with Prader-Willi\n      syndrome. Secondarily, the investigators will also perform evaluations to determine if\n      intranasal oxytocin has any effect on social skills, behaviors, or appetite in children with\n      Prader-Willi syndrome."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children with genetically confirmed PWS\n\n          -  Ages at \u2265 5 years and \u2264 11 years (must start treatment prior to 11th birthday)\n\n          -  Child must be in nutritional phase 2b or 3, as determined by the PI at each site.\n\n          -  Must currently be on growth hormone treatment, and have been receiving growth hormone\n             treatment for at least one year prior to screening date.\n\n          -  Treatment cannot have been interrupted for more than 1 week within 3 months prior to\n             screening date.\n\n          -  Priority will be given to children currently enrolled in the RDCRN Natural History\n             study\n\n        Exclusion Criteria:\n\n          -  Inability to tolerate intranasal administration of medication\n\n          -  Hepatic insufficiency (AST/ALT greater than 3 times the normal levels for age)\n\n          -  Renal insufficiency (BUN/Creatinine greater than 3 times the normal levels for age)\n\n          -  History of an abnormal ECG (as determined by a cardiologist).  If there is any\n             question about cardiac function, ECG reports will be reviewed with a cardiologist\n             prior to enrollment in the study.\n\n          -  Child not receiving growth hormone treatment\n\n          -  Child with hypertension or hypotension for age and sex (blood pressure >97% for age\n             and sex or blood pressure <3% for age and sex)\n\n          -  Diabetes mellitus\n\n          -  Pregnant or lactating.\n\n          -  Schizophrenia or psychosis\n\n          -  Taking any psychotropic medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013258", 
            "org_study_id": "5208"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intranasal oxytocin", 
                "description": "This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.", 
                "intervention_name": "Intranasal oxytocin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Pitocin", 
                    "Syntocinon"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days.  One month interval between arms of treatment.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxytocin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Prader Willi syndrome", 
            "Oxytocin"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "vkimonis@uci.edu", 
                    "last_name": "Virginia Kimonis, MD", 
                    "phone": "714-456-2942"
                }, 
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92686"
                    }, 
                    "name": "University of California, Irvine"
                }, 
                "investigator": {
                    "last_name": "Virginia Kimonis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "millejl@peds.uf.edu", 
                    "last_name": "Jennifer L Miller, MD", 
                    "phone": "352-334-1390"
                }, 
                "contact_backup": {
                    "email": "ckeeling@peds.ufl.edu", 
                    "last_name": "Christine Keeling, RN", 
                    "phone": "352-294-5280"
                }, 
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32610"
                    }, 
                    "name": "University of Florida"
                }, 
                "investigator": {
                    "last_name": "Jennifer L Miller, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mbutler4@kumc.edu", 
                    "last_name": "Merlin Butler, MD, PhD", 
                    "phone": "913-588-1873"
                }, 
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "University of Kansas Medical Center"
                }, 
                "investigator": {
                    "last_name": "Merlin Butler, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Oxytocin Trial in Prader-Willi Syndrome", 
        "other_outcome": [
            {
                "description": "Evaluation of anxiety, food issues, irritability, social communication and behavioral issues will be measured on days 1, 4 and 6 using:\nAberrant Behavior Checklist: Behavior rating scale used to measure behavior problems of children and adults with intellectual disabilities ages 6 - 54 years. Scores will range from 0 (no problem behaviors) to 174 (severe aberrant behaviors).\nSocial Responsiveness Scale:designed to measure the breadth of repetitive behaviors. Scores will range from 64 (no repetitive behaviors) to 260 (severe repetitive behaviors).\nRepetitive Behavior Scales-Revised: Designed to measure the breadth of repetitive behaviors in autism spectrum disorder including: Ritualistic/Sameness Behavior; Stereotypic Behavior; Self-injurious Behavior; Compulsive Behavior; and Restricted Interests. Scores will range from 0 (no autistic behaviors) to 100 (severe autistic behaviors).", 
                "measure": "Evaluation of social effects of intranasal oxytocin in children with Prader-Willi syndrome", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Evaluation of plasma OT, ghrelin and other neuroendocrine hormones involved in appetite regulation (cortisol, orexin A, ghrelin, leptin, oxytocin, insulin).", 
                "measure": "Effects of intranasal oxytocin on appetite-regulating hormones", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "overall_contact": {
            "email": "ckeeling@peds.ufl.edu", 
            "last_name": "Christine Keeling, RN", 
            "phone": "352-294-5280"
        }, 
        "overall_official": {
            "affiliation": "University of Florida", 
            "last_name": "Jennifer L Miller, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Federal Government", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Occurrence of adverse event, description and quantification of clinical and behavior severity, pre- and post- intranasal oxytocin and placebo administration.", 
            "measure": "Safety of intranasal oxytocin in children with Prader-Willi syndrome", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "reference": {
            "PMID": "21702900", 
            "citation": "Tauber M, Mantoulan C, Copet P, Jauregui J, Demeer G, Diene G, Rog\u00e9 B, Laurier V, Ehlinger V, Arnaud C, Molinas C, Thuilleaux D. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis. 2011 Jun 24;6(1):47."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013258"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Quantitative evaluation of hyperphagia via the Hyperphagia Questionnaire obtained on days 1, 4 and 6 during the 7 day study protocol and conducted in the evening on these days.  Score will range from 0 (no hyperphagia behaviors) to 96 (most severe hyperphagia behaviors).  Additionally quantity of food consumed will be recorded on Days 1,4, and 6.", 
            "measure": "Evaluation of food intake in Prader-Willi syndrome", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "University of Florida", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institutes of Health (NIH)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}